Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center


Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial ECOGHEME3903


Ancillary Laboratory Protocol for Collecting Diagnostic Material on Patients Considered for ECOG Treatment Trials for Leukemia or Related Hematologic Disorders

Principal Investigator(s)

Stephen Strickland


  • Protocol No. ECOGHEME3903
  • Open Date: 06/07/2005
  • Staging: N/A
  • Age Group: Adults
  • Scope: National
  • Objective: To provide a mechanism for sample collection and submission for diagnostic review to determine eligibility of patients for accrual to ECOG leukemia trials. To obtain baseline materials for correlative studies outlined in parent clinical protocols. No ECOG credit given
  • Disease Sites: Hematologic
  • Therapies: Correlative
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University; Univ of Florida - Gainesville
  • National Clinical Trial ID: NCT00897767
  • Secondary Protocol No: E3903


Patients are being asked to take part in this study because their physician suspects a type of blood or bone marrow cancer, which includes the chance of leukemia. Treatment will depend on the type of blood/bone marrow cell that is affected by this disease. We need to know what the genetic makeup of the diseased cells is so that we can find the best treatment for patients. Also, some treatment plans require that the diseased cells (such as leukemia cells) have a certain property, for instance, express a certain marker (cell structure) that is being targeted by this treatment. In addition to this, the study also prepares the samples for use in lab studies associated with the treatment trial that patients will be treated on if found eligible. Before a patient can enter the parent study, we need to find out whether they are eligible to take part in it. If we cannot determine the patients eligibility, they will not be able to take part in an ECOG study.


Ages Eligible for Study:N/A and older
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No


• Candidate for enrollment on an ECOG treatment clinical trial for acute or chronic leukemia
• Suspected clinical diagnosis and protocol ID number of the treatment clinical trial under consideration must be submitted to ECOG's Leukemia Translational Studies Laboratory to ensure that the required antibody panels are used and functional assays are performed
• Chosen ECOG treatment clinical trial must be active and accruing
• Patient must not have begun treatment on the ECOG treatment clinical trial
• Patient may be concurrently enrolled on this laboratory study and a treatment clinical trial if immediate treatment is medically necessary
• If subsequent diagnostic review alters the original diagnosis, the patient will be removed from the treatment clinical trial
• Not specified
• See Disease Characteristics